Outlook Pharma - רווח נקי למניה אחת בשנים עשר החודשים האחרונים OTLK

Outlook Therapeutics is creating an innovative environment for vision preservation by implementing a new standard of therapy for macular degeneration. The company relies on sustainable "green chemistry" and strict bioethics, while the stable operation of sterile filling lines ensures uninterrupted supplies. The share price history on GURU.Markets confirms these successes, with an EPS of 85.90, underscoring the fundamental resilience of the business.
פילוחי מדדים פיננסיים ומדדי שוק עבור Outlook Pharma (OTLK)

This indicator calculates the percentage change in net earnings per share over the last twelve months relative to the same period last year, measuring the scaling rate of real income. The trend in the annual EPS TTM growth rate allows for an assessment of the commercialization efficiency of certified bevacizumab and the speed of competitor displacement for Outlook Therapeutics (OTLK), confirming the fundamental resilience of the business by stabilizing metrics in the upper range.